Gilead Sciences Reports Q4 and Full-Year 2022 Financial Results
US major Gilead Sciences, Inc. (NASDAQ: GILD) last week reported Q4 and full-year 2022 financial...
Gilead Sciences
Cowell Health Partners with Gilead Sciences to Enhance Drug Accessibility
Cowell Health has announced a partnership with US-based Gilead Sciences, Inc., (NASDAQ: GILD) aimed at...
Innovent’s Parsaclisib Filed for Marketing Approval in China
China’s Center for Drug Evaluation (CDE) has received a marketing approval application for Innovent Biologics...
Fosun Kite’s Yescarta Gains Priority Review Status for r/r LBCL
China-based Fosun Kite Biotechnology Co., Ltd, a joint venture (JV) between Shanghai Fosun Pharmaceutical (Group)...
Beijing Launches HIV Precision Medicine Standardization Project
On September 17, an HIV precision medicine standardization project was initiated in Beijing. The project,...
Fudan-Zhangjiang’s JAK1 Inhibitor FZJ-003 Gel Enters Phase I Trial for Atopic Dermatitis
China-based Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd (HKG: 1349, SHA: 688505) announced that a Phase I...
Fosun Kite’s Yescarta CAR-T Therapy Secures New Clinical Trial Approval in China
Fosun Kite Biotechnology Co., Ltd, a joint venture between Shanghai Fosun Pharmaceutical (Group) Co., Ltd...
Gilead Transfers Trodelvy Asian Rights to Everest Medicines for USD280m
US pharmaceutical major Gilead Sciences Inc. (NASDAQ: GILD) today announced an agreement with Everest Medicines...